bebtelovimab: Clinical Trials

3 trials of bebtelovimab, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 completed, 1 terminated. 2 Phase 2, 1 Phase 3, 1 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 22Completed 2
Phase 31Completed 1
Phase 41Terminated 1

Follow bebtelovimab: new trials by email Literature Review of bebtelovimab trials Research Report on bebtelovimab

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
UPMC OPTIMISE-C19 Trial, a COVID-19 Study
Lilly Bamlanivimab, Regeneron Casirivimab + Imdevimab, Lilly Bamlanivimab + Etesevimab - Covid19
Phase 4TerminatedErin McCreary45712021-03-102023-06-15
A Study of Immune System Proteins in Participants With Mild to Moderate COVID-19 Illness
Bamlanivimab, Etesevimab, Placebo - COVID-19
Phase 2CompletedEli Lilly and Company17552020-10-292022-07-01
A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Participants With Mild to Moderate COVID-19 Illness
LY3819253, LY3832479, LY3853113 - COVID-19
Phase 2 / Phase 3CompletedEli Lilly and Company33072020-06-172024-04-11

Conditions studied

COVID-19 (3)

Sponsors

Eli Lilly and Company (2)  ·  Erin McCreary (1)

Countries

United States (3)  ·  Argentina (1)  ·  Puerto Rico (1)

Top investigators

David T Huang, MD, MPH (1)  ·  Erin McCreary, PharmD (1)

Results publications

PMID 34473343, PMID 35713300, PMID 34374951, PMID 33113295, PMID 33475701, PMID 34034784, PMID 34260849, PMID 34346827, PMID 34718468, PMID 35493124, PMID 35697146, PMID 35834252, PMID 37329415, PMID 38291279, PMID 39230829